The nine-month opposition period for the patent expired on August 8, 2007. The patent also has been granted in several other countries outside of Europe. Intellect Neurosciences is the exclusive assignee of the patent, which relates to the company’s Recall-Vax technology.
Dr Daniel Chain, chairman and CEO, said: “The validation of patent in Europe strengthens our competitive advantage in a therapeutic area that is a front runner in the attack against Alzheimer’s disease. We are excited about this promising technology that possesses a unique combination of safety features, which potentially enables it to be used to treat patients suffering from Alzheimer’s disease and also to prevent or delay the onset of this devastating disease.”